Objective-Cellular microparticles (MP) are promising biomarkers in many pathological situations. Although flow cytometry (FCM) is widely used for their measurement, it has raised controversies because the smallest MP size falls below the detection limit of standard FCM (sd-FCM). Following recent technological improvements leading to high sensitivity FCM (hs-FCM), our objectives were (1) to evaluate the potential of hs-FCM for extended MP detection, (2) to set up a standardized protocol for MP enumeration, and (3) to compare MP counts obtained with both sensitivity levels. Methods and Results-Compared with sd-FCM, hs-FCM displayed improved forward scatter resolution and lower background noise, allowing us to discriminate previously undetectable small MP in plasma samples. Using fluorescent beads with appropriate sizes (0.1/0.3/0.5/0.9 m) and relative amounts, a new standardized hs-FCM MP protocol was set up and provided reproducible MP counts. Applied to coronary patient samples, it resulted into 8-to 20-fold increases in MP counts as compared with sd-FCM. Interestingly, the ratio between small and large MP varied according to clinical status but also depending on MP subset, suggesting access to new biological information. Conclusion-Recent improvements in FCM provide access to previously undetectable MP and represent a new opportunity to enhance their impact as biomarkers in clinical practice. (Arterioscler Thromb Vasc Biol. 2012;32: 1054-1058.) (P.P., T.B., C.J., J.W.). The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
M icroparticles (MP) are submicron vesicles (size range, 0.1-1 m) released from cell membranes in response to activation or apoptosis. 1 They generally expose phosphatidylserine and membrane antigens representative of their parent cells. 2 MP behave as vectors of bioactive molecules, involved in various biological responses. [3] [4] [5] Circulating MP are elevated in many prothrombotic and inflammatory disorders; cardiovascular, autoimmune, and infectious diseases; and cancer. 4, [6] [7] [8] [9] [10] Although MP counts may provide useful diagnostic/prognostic information, assessment of their pathophysiological relevance is hampered by methodological concerns. Flow cytometry (FCM) is the most commonly used technique, 11 allowing both enumeration and characterization of MP cellular origin with high throughput. The forward scatter (FS) parameter is generally used to define the analysis gate for MP. Unfortunately, because of their limited FS sensitivity, standard flow cytometers measure only a small part of the MP population. Recently, high-sensitivity flow cytometers with significantly improved light scatter detection became available. As we first reported, these instruments resolve a previously undetectable subpopulation of small-size MPs. 12 Among the technical improvements found in high sensitivity FCM (hs-FCM), a new option of the Beckman Coulter Gallios called W2 increases FS resolution by amplifying the FS signals collected at large angles. 13 Whether this option can be used in a standardized manner, to improve the detection of MPs derived from platelets (PMP), erythrocytes (Ery-MP), leukocytes (Leu-MP), and endothelial cells (EMP), remains an open question. Our objectives were then (1) to evaluate the impact of high-sensitivity flow cytometer technical improvement on the detection of small-size MP, (2) to set up a new standardized protocol based on calibrated microbeads for MP enumeration, and (3) to compare MP counts obtained at both sensitivity levels of FCM.
Methods
Blood and plasma samples, MP preparation and flow cytometric analysis, size-conditioned MP filtration, intra-and inter-instrument reproducibility, and statistical analysis are described in the onlineonly Data Supplement. 
Results
Using fluorescence threshold and W2 option, a complete FS resolution between the 4 Megamixϩ beads was observed for hs-FCM, whereas it was limited to 0.5 m for standard FCM (sd-FCM) ( Figure 1A-1D ). Moreover, using FS threshold, background noise was also dramatically reduced in the 0.3 m bead FS area (100 -200 events/second versus overflow, data not shown). Altogether, FS resolution improvement and reduction of background noise provided by hs-FCM allowed routine analysis of events of interest in a 0.3 to 1 m bead-eq range.
We therefore evaluated the impact of this improved sensitivity on PMP detection using platelet free plasma samples from coronary patients. When the FS cutoff was progres- Left panels correspond to the respective control conditions. MPs above and below the 0.5 m bead-eq threshold appear as blue and red, respectively. sively lowered, the MP subsets observed in the 0.5 to 0.9 m bead-eq area ( Figures 1 and 2 , blue dots) were completed by previously undetectable MP characterized by lower fluorescence intensities in both Annexin V and CD41 staining ( Figures 1G, 1H , and Figure 2A , red dots). This subpopulation of small MP was also detectable for Ery-MP ( Figure 2B ), Leu-MP ( Figure 2C ), and EMP ( Figure 2D ). Noteworthy is the possibility of virtual double staining was excluded ( Figure  II in the online-only Data Supplement). Phospholipidic nature of the newly detected events was confirmed by removal after Triton X-100 treatment 14 (Figure III in the online-only Data Supplement).
A standardized protocol was then adapted based on the previously published Megamix strategy, 15 expanding the MP gate from a 0.5 to 1 m bead-eq to a 0.3 to 1 m bead-eq range ( Figure IA -ID in the online-only Data Supplement). The impact of slight FS cutoff variations around the 0.3 m bead area on MP counts being significant ( Figure IE in the online-only Data Supplement), it was important to establish a reproducible cutoff. Accordingly, CV of 5% (range, 2%-7%) and 10% (range, 2%-17%) for intra-and inter-instrument reproducibility, respectively, were obtained for PMP enumeration using samples from healthy individuals. To verify that differences in refractive index between beads and biological particles do not extensively affect FCM FS values, we performed differential filtration experiments using filters with precisely sized cylindrical pores. PMP enumerated in the 0.3 to 1 m bead-eq range MP gate were not affected after a 1 m filtration but totally depleted by a 0.2 m filtration ( Figure IV in the online-only Data Supplement). Interestingly, significant amount of particles passed through the 0.4 m filter indicating that the smallest MP detected by FCM using the Megamixϩ protocol display a size below 0.4 m.
Finally, MP counts obtained using sd-and hs-FCM were compared on 30 PFP from patient samples. Using hs-FCM, significantly more MP were detected with 6-, 7-, 9-, and 19-fold increases for Leu-MP, Ery-MP, PMP, and EMP, respectively, by reference to sd-FCM ( Table I in the onlineonly Data Supplement). Interestingly, when the ratio between small MP (0.3-0.5 m bead-eq) and large MP (0.5-1 m bead-eq) measured by hs-FCM was calculated, significant differences were observed not only between healthy subjects and coronary patients (Pϭ0.0003, 0.02, 0.002, and 0.0003 for PMP, Ery-MP, Leu-MP, and EMP, respectively). We also observed a difference according to the MP subset, with a more pronounced variation for Leu-MP and EMP subsets (Table) .
Discussion
In this study, we provided evidence that compared with sd-FCM, hs-FCM displayed improved FS resolution and decreased background noise, allowing resolution of previously undetectable small-size MP subpopulations derived from platelets, erythrocytes, endothelial cells and leukocytes. We further validated the use of calibrated fluorescent beads covering the size range of MP to design a new standardized protocol providing reproducible MP counts. Translation of this protocol to pathological samples resulted in a significant increase in the number of MPs detected with hs-FCM as compared with sd-FCM.
As previously shown by electron microscopy, 14 new techniques such as laser-induced nanotracking, 16, 17 atomic force microscopy, 18, 19 and dynamic light scattering [20] [21] [22] recently confirmed that the major part of MP counts falls below the detection threshold of sd-FCM. However, recent FCM innovations strive for an MP numeration closer to these sensitive techniques while giving supplemental information such as immuno-phenotype. The next step will be to investigate the correlation between the data provided by these different methodologies.
To date, the few studies published 23, 24 that have already used this type of cytometers did not define the lower limit of analysis, impeding future comparisons. Thus, using a standardization strategy, we defined an accurate MP gate between 1 and 0.3 m bead-eq as the best compromise between a good FS resolution and a level of background noise that does not impede the cytometer performance. The use of polystyrene beads remains an imperfect model for general size calibration in FCM. 24 However, we demonstrated that FS-based sizing in hs-FCM is closed between beads and MP, as shown in differential filtration experiments and in recent published data using a very large virus with a refractive index more comparable to that of biological samples than that of beads. 25 Access to small-size MP resulted in a 8-to 20-fold increase in the number of MP enumerated in pathological samples. Interestingly the ratio between small and large particles varies not only according to the clinical status (healthy donors versus patients) but also according to MP subset, the most dramatic changes being observed for EMP and Leu-MP, which remain subpopulations present in lower amounts in plasma and are hardly detectable by sd-FCM. These differences suggest access to new information provided by the previously undetectable subpopulations of MP. This is consistent with the lack of correlation between sd-and hs-FCM when counting both EMP and LeuMP subsets (data not shown).
In conclusion, access to standardized measurement of small-size MP is an exciting prospect that opens new questions: do they rely on the same mechanism of formation as large-size MP? Do they have the same biological functions? What is their clinical relevance to identifying patients with vascular risk or monitoring response to treatment? Addressing these challenging questions is mandatory to decipher the new information provided by small-size MP. 
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